Several genetic alterations have been suggested to drive the pathogenesis of ERMS, including enhanced RAS signaling with mutations in KRAS, NRAS, and HRAS; activation of Hedgehog (Hh) signaling; and inactivation of p53 and Rb pathways [73]. The gene discussed is TP53; the disease is embryonal rhabdomyosarcoma.